BMS Continues to Lead the Advancemen?t of Immuno-Onc?ology with Broad Set of New Data at 2014 ASCO Annual Meeting

Bristol-Myers Squibb Company (BMS) has announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 30 May–3 June. BMS has been at the forefront of research and discovery in the field of immuno-oncology and these data add to the growing body of research from its leading immuno-oncology pipeline, further supporting the scientific rationale for the potential of these checkpoint inhibitors as single agents or as part of a combination regimen.

“We believe that immuno-oncology has the potential to be significant in the treatment of cancer and to have broad applicability across multiple tumor types and lines of therapy,” said Francis Cuss, MB BChir, FRCP, executive vice president and chief scientific officer, BMS. “The data to be presented from our immuno-oncology pipeline — including longer-term follow up results, combination data in multiple tumour types, biomarker analyses, and findings in earlier lines of treatment — continue to demonstrate our commitment to leading scientific advances in this area. We are focused on the goal of changing survival expectations and the way that patients live with cancer.”

For full details, click here.